
Nicholai N Klimko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/524307/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Advances, 2022, 6, 2427-2433.	2.5	46
2	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood, 2022, 139, 1588-1592.	0.6	70
3	Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a <i>Post Hoc</i> Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study. Journal of Clinical Microbiology, 2022, 60, e0229821.	1.8	17
4	Intravenous posaconazole: key features of clinical pharmacology and practical applications. Oncogematologiya, 2022, 17, 121-133.	0.1	0
5	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Advances, 2022, 6, 3870-3874.	2.5	8
6	Characterization and outcome of invasive infections due to <i>Paecilomyces variotii</i> : analysis of patients from the FungiScope® registry and literature reports. Journal of Antimicrobial Chemotherapy, 2021, 76, 765-774.	1.3	22
7	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	4.6	586
8	Sensitization to Aspergillus spp. in patients with asthma. Vrach, 2021, 32, 50-55.	0.0	1
9	Chronic Aspergillosis in the Guise of Peripheral Lung Neoplasia. Vestnik Rentgenologii I Radiologii, 2021, 102, 47-56.	0.1	0
10	Comparative pharmacoeconomic analysis of posaconazole therapy in tablet form and in suspension for invasive fungal infections prevention. Oncogematologiya, 2021, 16, 94-107.	0.1	1
11	Invasive fungal infection of the central nervous system caused by rare yeast pathogen <i>Malassezia spp.</i> in patients with acute leukemia: case reports and literature review. UÄenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2021, 27, 80-87.	0.0	0
12	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	6.9	189
13	Chronic Pulmonary Aspergillosis: Literature Review and Demonstration of Own Observations. Vestnik Rentgenologii I Radiologii, 2021, 102, 317-328.	0.1	Ο
14	Immunological markers of inflammation in patients with asthma with sensitization to Aspergillus spp. Vrach, 2021, 32, 74-79.	0.0	0
15	COVID-19-Associated Pulmonary Aspergillosis in Russia. Journal of Fungi (Basel, Switzerland), 2021, 7, 1059.	1.5	12
16	ECMM <i>Candi</i> Reg—A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	1.8	19
17	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	4.6	970
18	Molecular Diagnostics of Mucormycosis in Hematological Patients: A Literature Review. Journal of Fungi (Basel, Switzerland), 2019, 5, 112.	1.5	8

Nicholai N Klimko

#	Article	IF	CITATIONS
19	Comparative clinical and economic analysis of pozaconazol (Noxafil) for invasive mycoses (IM) prevention in patients with severe neutropenia during treatment of acute myeloid leukemia or myelodysplastic syndrome. Oncogematologiya, 2019, 14, 49-59.	0.1	3
20	Breakthrough invasive candidiasis in pediatric patient with Ewing's sarcoma: dinical case report and literature review. Oncogematologiya, 2019, 14, 59-66.	0.1	3
21	Invasive aspergillosis in children and adolescents with solid tumors: clinical cases and registry analysis. Oncogematologiya, 2019, 14, 40-48.	0.1	1
22	Invasive aspergillosis in children in debut of acute myeloid leukemia. Pediatric Hematology/Oncology and Immunopathology, 2019, 18, 88-95.	0.1	1
23	Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation). Oncogematologiya, 2019, 14, 90-97.	0.1	0
24	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses, 2018, 61, 885-894.	1.8	52
25	Disseminated Fusariosis in Immunocompromised Children—Analysis of Recent Cases Identified in the Global Fungiscope Registry. Pediatric Infectious Disease Journal, 2017, 36, 230-231.	1.1	18
26	FungiScope [™] —Global Emerging Fungal Infection Registry. Mycoses, 2017, 60, 508-516.	1.8	47
27	Invasive Aspergillosis in Patients with Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia in St Petersburg, Russia. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
28	Mold Allergy in Cystic Fibrosis Patients. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
29	Invasive fungal diseases in adolescents and young adults after allogeneic hematopoietic stem cell transplantation. Cellular Therapy and Transplantation, 2016, 5, 71-74.	0.2	0
30	The case of diagnostics of invasive pulmonary aspergillosis by in vivo probe-based confocal laser endomicroscopy of central and distal airways. Medical Mycology Case Reports, 2014, 5, 35-39.	0.7	14
31	Triggers for driving treatment of at-risk patients with invasive fungal disease. Journal of Antimicrobial Chemotherapy, 2013, 68, iii17-iii24.	1.3	14
32	EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clinical Microbiology and Infection, 2012, 18, E246-E247.	2.8	368
33	EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clinical Microbiology and Infection, 2012, 18, E248-E250.	2.8	108
34	Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA). Mycoses, 2011, 54, e148-e153.	1.8	1
35	Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clinical Microbiology and Infection, 2011, 17, 1859-1867.	2.8	566
36	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. Journal of Clinical Microbiology, 2009, 47, 117-123.	1.8	205

#	Article	IF	CITATIONS
37	EUCAST Technical Note on fluconazole. Clinical Microbiology and Infection, 2008, 14, 193-195.	2.8	83
38	Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis : a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology, 2008, 46, 842-849.	1.8	96
39	Caspofungin for the treatment of less common forms of invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2007, 60, 363-369.	1.3	122